Description

Insmed Incorporated is a biopharmaceutical company primarily focused on discovering, developing, and marketing therapeutic solutions for individuals afflicted with severe and rare medical conditions. The company's marketed product, ARIKAYCE, is prescribed to adult patients as part of a multi-drug antibacterial regimen for the treatment of Mycobacterium avium complex lung disease. In its robust development pipeline, Insmed is progressing Brensocatib, an oral, reversible dipeptidyl peptidase 1 inhibitor, which targets bronchiectasis and other diseases mediated by neutrophils. Another key investigational therapy is Treprostinil Palmitil Inhalation Powder, an inhaled formulation of the treprostinil prodrug, treprostinil palmitil, designed to address pulmonary arterial hypertension and various other uncommon pulmonary disorders. Founded in 1988, Insmed Incorporated maintains its corporate headquarters in Bridgewater, New Jersey.